Oncology

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

SpotitEarly's novel platform combines trained dogs and machine learning for non-invasive cancer detection. A new partnership aims to bring it to market by 2027.

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

Colorado's largest cancer practice adopts Canopy's enterprise AI, a strategic move to boost efficiency, personalize care, and set a new tech standard.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

As Corrixr's novel CRISPR therapy nears human trials, the appointment of Seagen veteran Nancy Whiting signals a strategic shift from lab to market.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

Elephas Biosciences adds legendary oncologist Dr. Skip Burris to its board, a pivotal move to commercialize a platform that predicts immunotherapy success.

A new nonprofit is using tax-exempt bonds to fight healthcare consolidation. Is Anoma Cancer Collective's model a lifeline for local cancer care?

As corporate consolidation swallows local clinics, a new nonprofit network offers a lifeline to keep cancer care independent, accessible, and human-centered.

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

With bladder cancer recurrence rates stubbornly high, UroGen Pharma is advancing a novel oncolytic virus into human trials. Can it finally break the cycle?

GeneCentric's ExpressCT Rewind™ uses fragmentomics to mine gene expression data from old liquid biopsies, offering a cost-effective way to find new biomarkers.

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

Avacta taps veteran dealmaker Dr. Patrick Vink as it nears a pivotal data reveal for its pre|CISION® platform, signaling a shift from R&D to high-stakes commercial strategy.

With the appointment of Vita S. Salsman, Immunocine signals a major push to translate its unique "Double Loaded" dendritic cell therapy from lab to clinic.

WellSpan Health's integration with a top local oncology practice promises better care through tech and scale. But does this move signal a brighter future for patients or a troubling trend of market consolidation?

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.